Vancouver, British Columbia - Clusterin, a stress-related protein, appears to inhibit apoptosis associated with androgen withdrawal and may therefore be an important therapeutic target in men with advanced prostate cancer, say researchers from the University of British Columbia.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.